Abstract
Introduction Mucus pathology plays a critical role in airway diseases like chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD). Up to 32% of community-living persons report clinical manifestations of mucus pathology (e.g., cough and sputum production). However, airway mucus pathology has not been systematically studied in community-living individuals. In this study, we will use an objective, reproducible assessment of mucus pathology on chest computed tomography (CT) scans from community-living individuals participating in the Coronary Artery Risk Development in Young Adults (CARDIA) and Framingham Heart Study (FHS) cohorts.
Methods and analysis We will determine the clinical relevance of CT-based mucus plugs and modifiable and genetic risk and protective factors associated with this process. We will evaluate the associations of mucus plugs with lung function, respiratory symptoms, and chronic bronchitis and examine whether 5-yr. persistent CT-based mucus plugs are associated with the decline in FEV1 and future COPD. Also, we will assess whether modifiable factors, including air pollution and marijuana smoking are associated with increased odds of CT-based mucus plugs and whether cardiorespiratory fitness is related in an opposing manner. Finally, we will determine genetic resilience/susceptibility to mucus pathology. We will use CT data from the FHS and CARDIA cohorts and genome-wide sequencing data from the TOPMed initiative to identify common and rare variants associated with CT-based mucus plugging.
Ethics and Dissemination The Mass General Brigham Institutional Review Board approved the study. Findings will be disseminated through peer-reviewed journals and at professional conferences.
Strengths and limitations of this study
Utilization of data from two well-characterized large community-based US cohorts.
Use of chest CT scans to identify and quantify mucus plugs, providing a more objective and reproducible measure of airway pathology.
Use of whole-genome sequencing to identify common and rare genetic variants associated with mucus pathology.
Only the inclusion of participants self-identified as non-Hispanic white and non-Hispanic black.
A limitation of retrospective study design using prospectively collected data.
Competing Interest Statement
Maya Abdalla and Rim Elalami have no conflict of interests to disclose. Dr Cho reported receiving grants from Bayer. Dr O Connor reports no conflict of interests. Dr Rice reported receiving research grant funding from the NIH and receiving expert testimony fees from the Conservation Law Foundation. Dr Horowitz reported consulting fees from Bayer and is a member of GE medical imaging advisory board. Dr Akhoundi had no conflicts of interest to disclose. Dr Yen reported receiving salary support. Dr Kalhan reported grants from AstraZeneca, PneumRx/BTG and Spiration to Northwestern University, consulting fees from CVS Caremark, AstraZeneca, GlaxoSmithKline, and CSA Medical, payment from GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim and is a member of CSA Medical advisory board. Dr Diaz reported receiving personal fees from Boehringer Ingelheim and having a patent for Methods and Compositions Relating to Airway Dysfunction pending (701586-190200USPT).
Funding Statement
This work was supported by the National Heart Lung and Blood Institute (Grant R01-HL164824). The Coronary Artery Risk Development in Young Adults Study (CARDIA) is supported by contracts 75N92023D00002, 75N92023D00003, 75N92023D00004, 75N92023D00005, and 75N92023D00006 from the National Heart, Lung, and Blood Institute (NHLBI). The funders of this project were not involved in the writing, editing, or decision to publish this study. This manuscript was reviewed and approved by the CARDIA Publications and Presentations Committee.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Mass General Brigham Institutional Review Board gave ethical approval for this work (2022P000723). This work was supported by the National Heart Lung and Blood Institute (Grant R01-HL164824).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
